Dermatologische Klinik des Universitätsspitals Basel

Zusammenfassung

Die Dermatologische Klinik des Universitätsspitals Basel vereint die Disziplinen Dermatologie, Venerologie und Allergologie inkl. klinischer Immunologie. Sie zeichnet sich durch Patientenversorgung, Forschung und Weiterbildung auf universitärem Niveau aus. Mit ihrer 109-jährigen Geschichte bietet die Klinik ein breites Spektrum an evidenzbasierten Möglichkeiten in Diagnostik und Therapie. Unser Team erforscht und integriert kontinuierlich die neuesten Möglichkeiten der medizinischen und ästhetischen Dermatologie, der Allergologie, der 3D-Hautkrebsvorsorge und der Mohs-Chirurgie. Neben der Dermatologischen Poliklinik mit allgemeiner Sprechstunde und Notfalldienst verfügt die Klinik über eine wachsende Allergologische Poliklinik und eine stationäre Dermatologie mit 12 Betten, die ein breites Spektrum moderner dermatologischer Behandlungen anbietet. Hinzu kommt die 2019 gegründete Margarethenklinik als Zentrum für Ästhetik und Rekonstruktion. Verschiedene Spezialsprechstunden, eine Abteilung für Dermatopathologie, 2 Operationssäle sowie Bereiche für Lehre und Forschung runden das umfassende Angebot ab. Schwerpunkte der klinischen Forschung sind entzündliche Hauterkrankungen, allergologische Erkrankungen und Dermatoonkologie. Die Klinik forscht intensiv im Bereich der Biomedizin und der digitalen Dermatologie, insbesondere unter Verwendung von KI-Techniken zur Analyse von Hautbildern. Sie ist bestrebt, klinische Innovationen in der Dermatologie und Allergologie voranzutreiben mit Schwerpunkt auf digitalen Lösungen und der Verbindung von medizinischer und ästhetischer Dermatologie.

Abstract

The Department of Dermatology of the University Hospital Basel combines the fields of dermatology, venereology and allergology including clinical immunology. It is characterized by inspired, university-based patient care, research and continuing education. With its 109-year history, the Department of Dermatology offers a broad spectrum of evidence-based options in diagnostics and therapy. Our team continuously explores and integrates the latest options in medical and aesthetic dermatology, allergology, 3D skin cancer screening and Mohs surgery. In addition to the Outpatient Dermatology Clinic, which offers general and emergency consultations, the department has a growing Division of Allergy and a 12-bed Inpatient Dermatology Unit that offers a wide range of modern dermatological treatments. There is also the “Margarethenklinik”, established in 2019, which represents a Center for Aesthetics and Reconstruction. Various specialty clinics, a Dermatopathology Unit, a Surgical Unit with two operation theaters, and educational and research activities are also part of the extensive services offered. Our clinical research focuses on inflammatory skin diseases, allergic diseases, and dermatooncology. The Department conducts intensive research in biomedicine and digital dermatology, particularly using AI techniques to analyze skin images. It strives to drive innovation in dermatology and allergology, with a focus on digital solutions and combining medical and aesthetic dermatology.

Publikationsverlauf

Artikel online veröffentlicht:
19. Oktober 2023

• Literatur

• 1 Allouche J. et al. NNT mediates redox-dependent pigmentation via a UVB- and MITF-independent mechanism. Cell 2021; 184: 4268-4283
• 2 Brandt O, Christophers E, Fölster-Holst R. Halo dermatitis followed by the development of vitiligo associated with Suttonʼs nevi. J Am Acad Dermatol 2005; 52 (Suppl. 01) S101-S104 DOI: 10.1016/j.jaad.2004.08.025. (PMID: 15858503)
• 3 Erni B. et al. Proposition of a severity scale for lichen sclerosus: The “Clinical Lichen Sclerosus Score”. Dermatol Ther 2021; 34: e14773 DOI: 10.1111/dth.14773. (PMID: 33426761)
• 4 Peev A. et al. More than words: Itch perception visualized by patientsʼ drawings. J Eur Acad Dermatol Venereol 2022; 36: e638-e640
• 5 Chee A. et al. When life is an itch: What harms, helps, and heals from the patients’ perspective? Differences and similarities among skin diseases. Dermatol Ther 2020; 33: e13606
• 6 Tamschick R. et al. Insomnia and other sleep disorders in dermatology patients: A questionnaire-based study with 634 patients. Clin Dermatol 2021; 39: 996-1004
• 7 Sutter M. et al. Contagious itch, disgust and empathy in a family with scabies and their treating medical staff: An exploratory study. Acta Derm Venereol 2022; 102: adv00816
• 8 Baschong A. et al. Itch reduction using immersive virtual reality – An experimental pilot study. Dermatol Ther 2021; 34: e15001 DOI: 10.1111/dth.15001. (PMID: 34036696)
• 9 Mueller SM. et al. Pruritic and antipruritic colors: An exploratory pilot study. Dermatol Ther 2020; 33: e13447 DOI: 10.1111/dth.13447. (PMID: 32323448)
• 10 Polat G. et al. Three patients with chronic vulvar pruritus successfully treated with cold atmospheric pressure plasma. J Dtsch Dermatol Ges 2021; 19: 1346-1349
• 11 Merkel TA, Navarini A, Mueller S. Differences in phototherapy among skin diseases and genders in real-life conditions – A retrospective analysis of the cumulative doses, numbers of sessions, side effects and costs in 561 patients. Photodermatol Photoimmunol Photomed 2021; 37: 464-473 DOI: 10.1111/phpp.12683. (PMID: 33793982)
• 12 Feuchter S. et al. Repair of a cartilaginous crus of helix defect on the ear. Dermatol Surg 2023; 49: 791-793 DOI: 10.1097/DSS.0000000000003814. (PMID: 37134241)
• 13 Kunz M, Clark D, Somani AK. Repair of dual perialar defects on the upper cutaneous lip. Dermatol Surg 2021; 47: 985-987 DOI: 10.1097/DSS.0000000000002338. (PMID: 32058418)
• 14 May A, Kunz M, Somani AK. Versatile use of a surgical marker in delicate deep Mohs micrographic surgery layers. Int J Dermatol 2020; 59: e39-e40 DOI: 10.1111/ijd.14660. (PMID: 31556106)
• 15 Cerci FB. et al. “Stretching dermoscopy” to delineate the margins of basal cell carcinoma on photodamaged telangiectatic skin. Dermatol Pract Concept 2023; 13: e2023148 DOI: 10.5826/dpc.1302a148. (PMID: 37196287)
• 16 Zehnder M. et al. Radiotherapy as a treatment option for local disease control in primary cutaneous diffuse large B-cell lymphoma, leg type. Dermatology 2022; 238: 967-976 DOI: 10.1159/000522053. (PMID: 35158362)
• 17 Galadari H. et al. Complication of soft tissue fillers: Prevention and management review. J Drugs Dermatol 2020; 19: 829-832 DOI: 10.36849/JDD.2020.10.36849/JDD.2020.5084. (PMID: 33026743)
• 18 Vasconcelos-Berg R. et al. Doppler ultrasound-guided filler injections: Useful tips to integrate ultrasound in daily practice. Aesthet Surg J 2023; 43: 773-783 DOI: 10.1093/asj/sjac353. (PMID: 36594153)
• 19 Goekcimen K. et al. Addressing patient safety hazards using critical incident reporting in hospitals: A systematic review. J Patient Saf 2023; 19: e1-e8 DOI: 10.1097/PTS.0000000000001072. (PMID: 35985209)
• 20 Jahn AS. et al. Over-detection of melanoma-suspect lesions by a CE-certified smartphone app: Performance in comparison to dermatologists, 2D and 3D convolutional neural networks in a prospective data set of 1204 pigmented skin lesions involving patientsʼ perception. Cancers (Basel) 2022; 14: 3829 DOI: 10.3390/cancers14153829. (PMID: 35954491)
• 21 Kostner L. et al. Effects of COVID-19 lockdown on melanoma diagnosis in Switzerland: Increased tumor thickness in elderly females and shift towards stage IV melanoma during lockdown. Cancers (Basel) 2022; 14: 2360
• 22 Gotlib J. et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 2016; 374: 2530-2541 DOI: 10.1056/NEJMoa1513098. (PMID: 27355533)
• 23 Hartmann K. et al. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol 2020; 146: 356-366
• 24 Gotlib J. et al. Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. Expert Opin Biol Ther 2021; 21: 487-498
• 25 Gotlib J. et al. Avapritinib versus placebo in indolent systemic mastocytosis. NEJM Evid 2023; 2 DOI: 10.1056/EVIDoa2200339.
• 26 Bürgler A. et al. Rationale and design of a panel study investigating six health effects of airborne pollen: The EPOCHAL study. Front Public Health 2021; 9: 689248 DOI: 10.3389/fpubh.2021.689248. (PMID: 34222186)
• 27 Gotlib J. et al. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) response criteria in advanced systemic mastocytosis. J Allergy Clin Immunol Pract 2022; 10: 2025-2038
• 28 Valent P. et al. European Competence Network on Mastocytosis (ECNM): 20-year jubilee, updates, and future perspectives. J Allergy Clin Immunol Pract 2023; 11: 1706-1717 DOI: 10.1016/j.jaip.2023.02.021. (PMID: 36868470)
• 29 Dölle-Bierke S. et al. Food-induced anaphylaxis: Data from the European Anaphylaxis Registry. J Allergy Clin Immunol Pract 2023; 11: 2069-2079
• 30 Kennedy VE. et al. Mast cell leukemia: Clinical and molecular features and survival outcomes of patients in the ECNM Registry. Blood Adv 2023; 7: 1713-1724 DOI: 10.1182/bloodadvances.2022008292. (PMID: 36094848)
• 31 Trizuljak J. et al. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. Allergy 2020; 75: 1927-1938
• 32 Kluin-Nelemans HC. et al. Prognostic impact of eosinophils in mastocytosis: Analysis of 2350 patients collected in the ECNM Registry. Leukemia 2020; 34: 1090-1101 DOI: 10.1038/s41375-019-0632-4. (PMID: 31740811)
• 33 Navarini AA. et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 1792-1799 DOI: 10.1111/jdv.14386. (PMID: 28585342)
• 34 Maul JT. et al. Gender and age significantly determine patient needs and treatment goals in psoriasis – A lesson for practice. J Eur Acad Dermatol Venereol 2019; 33: 700-708
• 35 Maul JT. et al. Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study. Br J Dermatol 2021; 185: 1160-1168 DOI: 10.1111/bjd.20387. (PMID: 33837519)
• 36 Anzengruber F. et al. Smoking does not alter the therapy response to systemic anti-psoriatic therapies: A two-country, multi-centre, prospective, Non-interventional study. Acta Derm Venereol 2019; 99: 871-877
• 37 Hunger RE. et al. Swiss practice recommendations for the management of hidradenitis suppurativa/acne inversa. Dermatology 2017; 233: 113-119 DOI: 10.1159/000477459. (PMID: 28683447)
• 38 Walss M. et al. Implementing medical chatbots: An application on hidradenitis suppurativa. Dermatology 2021; 237: 712-718 DOI: 10.1159/000511706. (PMID: 33744903)
• 39 Higgins R. et al. Generalized comedones, acne, and hidradenitis suppurativa in a patient with an FGFR2 missense mutation. Front Med (Lausanne) 2017; 4: 16
• 40 Jungo P. et al. Superiority in quality of life improvement of biologics over conventional systemic drugs in a Swiss real-life psoriasis registry. Dermatology 2016; 232: 655-663 DOI: 10.1159/000455042. (PMID: 28103601)
• 41 Mueller SM. et al. The relationship between PASI and DLQI with itch, stress, and depression: Do we need additional decision-making tools in psoriasis?. Dermatol Ther 2020; 33: e13276
• 42 Burden AD. et al. Clinical disease measures in generalized pustular psoriasis. Am J Clin Dermatol 2022; 23 (Suppl. 01) 39-50 DOI: 10.1007/s40257-021-00653-0. (PMID: 35061231)
• 43 Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol 2022; 23 (Suppl. 01) 21-29 DOI: 10.1007/s40257-021-00654-z. (PMID: 35061227)
• 44 Hirsiger JR. et al. Anaphylaxis to goatʼs and sheep’s milk in an adult who tolerated cow’s milk: A sensitization profile study. J Investig Allergol Clin Immunol 2022; 32: 154-156 DOI: 10.18176/jiaci.0721. (PMID: 34160350)
• 45 Recke A. et al. Identification of the recently described plasminogen gene mutation p.Lys330Glu in a family from Northern Germany with hereditary angioedema. Clin Transl Allergy 2019; 9: 9
• 46 Huang K. et al. Artificial intelligence-based psoriasis severity assessment: Real-world study and application. J Med Internet Res 2023; 25: e44932 DOI: 10.2196/44932. (PMID: 36927843)
• 47 Navarini AA. et al. Genome-wide association study identifies three novel susceptibility loci for severe acne vulgaris. Nat Commun 2014; 5: 4020 DOI: 10.1038/ncomms5020. (PMID: 24927181)
• 48 Petridis C. et al. Genome-wide meta-analysis implicates mediators of hair follicle development and morphogenesis in risk for severe acne. Nat Commun 2018; 9: 5075 DOI: 10.1038/s41467-018-07459-5. (PMID: 30542056)
• 49 Kuhn-Régnier S. et al. A report of two cases of solid facial edema in acne. Dermatol Ther (Heidelb) 2017; 7: 167-174 DOI: 10.1007/s13555-017-0173-6. (PMID: 28168623)
• 50 Meier-Schiesser B. et al. Culprit drugs induce specific IL-36 overexpression in acute generalized exanthematous pustulosis. J Invest Dermatol 2019; 139: 848-858 DOI: 10.1016/j.jid.2018.10.023. (PMID: 30395846)
• 51 Satoh TK. et al. IL-36gamma drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest 2020; 130: 1417-1430 DOI: 10.1172/JCI128678. (PMID: 31805013)
• 52 Amruthalingam L. et al. Quantification of efflorescences in pustular psoriasis using deep learning. Healthc Inform Res 2022; 28: 222-230 DOI: 10.4258/hir.2022.28.3.222. (PMID: 35982596)
• 53 Amruthalingam L. et al. Improved diagnosis by automated macro- and micro-anatomical region mapping of skin photographs. J Eur Acad Dermatol Venereol 2022; 36: 2525-2532 DOI: 10.1111/jdv.18476. (PMID: 35924423)
• 54 Amruthalingam L. et al. Objective hand eczema severity assessment with automated lesion anatomical stratification. Exp Dermatol 2023; 32: 521-528
• 55 Gonzalez-Jimenez A. et al. SANO: Score-based anomaly localization for dermatology, in Proceedings of the 1st Workshop on Scarce Data in Artificial Intelligence for Healthcare – SDAIH. SciTePress. 2023
• 56 Gonzalez-Jimenez A. et al. Robust T-loss for medical image segmentation. arXiv preprint arXiv:2306.00753. 2023
• 57 Greis C. et al. Artificial intelligence to support telemedicine in Africa. Hautarzt 2020; 71: 686-690 DOI: 10.1007/s00105-020-04664-6. (PMID: 32761386)
• 58 Kirsch M. et al. Presence of neoplastic mast cells in ascites in advanced systemic mastocytosis. J Allergy Clin Immunol Pract 2022; 10: 3035-3038
• 59 Rabenhorst A. et al. Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity. J Allergy Clin Immunol 2016; 137: 314-318
• 60 Konantz M. et al. Increased TIM-3 and galectin-9 serum levels in patients with advanced systemic mastocytosis. J Allergy Clin Immunol. 2023
• 61 Hartmann K. et al. Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients. J Allergy Clin Immunol 2013; 132: 232-235
• 62 Rabenhorst A. et al. Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol 2013; 132: 1234-1237
• 63 Konantz M. et al. MRGPRX2: A novel biomarker in mastocytosis?. J Allergy Clin Immunol Pract 2023; 11: 669-671 DOI: 10.1016/j.jaip.2022.10.053. (PMID: 36759088)
• 64 Gerbaulet A. et al. Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit. Blood 2011; 117: 2012-2021